Signing the deal: (L) Dr Raja Mugasimangalam, president, founder & CEO, Genotypic Technology; and (R) Prof S R Shankapal, vice chancellor, M S Ramaiah University of Applied Sciences (MSRUAS)
The MoU has been signed for 4 years. MSRUAS will be paying Rs 50 lakh to Genotypic Technology under the terms of the deal.
The prevalence of oral cancer is said to be common in India. "The age-adjusted rates of oral cancer vary from over 20 per 100,000 populations in India, to 10 per 100,000 in the United States, and less than 2 per 100,000 in the Middle East. In comparison with the US population, where oral cavity cancer represents only about 3 percent of malignancies, it accounts for over 30 percent of all cancers in India," opined Dr Roopa Rao, professor & HOD, department of oral pathology, faculty of dental sciences, MSRUAS.
In the current scenario, biomarkers or PCR techniques are extremely important in cancer research which help identify the target organism and vaccine preparation.
"Genomics is not a science. It is a tool with immense power and potential, and is being applied in every area today. This collaboration is mainly going to bring in exposure on genomics knowledge to clinicians and its practical applications for patients, since genomics is usually used more for research purposes than for treatments," said Dr Raja Mugasimangalam, president, founder & CEO, Genotypic Technology.
All the current intellectual properties (IPs) owned by Genotypic and MSRUAS will be owned by the respective parties.